LV11803B - NON-PLAYING GP350 / 220 OPTION - Google Patents

NON-PLAYING GP350 / 220 OPTION Download PDF

Info

Publication number
LV11803B
LV11803B LVP-96-430A LV960430A LV11803B LV 11803 B LV11803 B LV 11803B LV 960430 A LV960430 A LV 960430A LV 11803 B LV11803 B LV 11803B
Authority
LV
Latvia
Prior art keywords
thr
pro
ser
amino acid
protein
Prior art date
Application number
LVP-96-430A
Other languages
English (en)
Latvian (lv)
Other versions
LV11803A (lv
Inventor
Richard Spaete
Winthrop T. Jackman
Original Assignee
Aviron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aviron filed Critical Aviron
Publication of LV11803A publication Critical patent/LV11803A/xx
Publication of LV11803B publication Critical patent/LV11803B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Fats And Perfumes (AREA)
  • Polarising Elements (AREA)
LVP-96-430A 1994-04-18 1996-11-12 NON-PLAYING GP350 / 220 OPTION LV11803B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22929194A 1994-04-18 1994-04-18
PCT/US1995/004611 WO1995028488A1 (fr) 1994-04-18 1995-04-13 VARIANTES NON EPISSABLES DES gp 350 ET 220

Publications (2)

Publication Number Publication Date
LV11803A LV11803A (lv) 1997-06-20
LV11803B true LV11803B (en) 1998-01-20

Family

ID=22860582

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-430A LV11803B (en) 1994-04-18 1996-11-12 NON-PLAYING GP350 / 220 OPTION

Country Status (25)

Country Link
US (3) US6054130A (fr)
EP (1) EP0769056B1 (fr)
JP (4) JP3447743B2 (fr)
KR (1) KR100380953B1 (fr)
CN (2) CN1118573C (fr)
AT (1) ATE210184T1 (fr)
AU (1) AU707837B2 (fr)
BR (1) BR9507473A (fr)
CA (1) CA2187908C (fr)
CZ (1) CZ292283B6 (fr)
DE (1) DE69524415T2 (fr)
DK (1) DK0769056T3 (fr)
ES (1) ES2170144T3 (fr)
FI (2) FI118224B (fr)
HU (1) HU221647B1 (fr)
LV (1) LV11803B (fr)
MY (1) MY114769A (fr)
NO (1) NO319382B1 (fr)
PL (1) PL181881B1 (fr)
PT (1) PT769056E (fr)
RU (1) RU2178807C2 (fr)
SK (1) SK283446B6 (fr)
TW (1) TW496897B (fr)
UA (1) UA47403C2 (fr)
WO (1) WO1995028488A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
US6692749B1 (en) * 1994-04-18 2004-02-17 Medimmune Vaccines, Inc. Non-splicing variants of gp350/220
AU2582897A (en) * 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
WO1999029848A1 (fr) * 1997-12-05 1999-06-17 The Immune Response Corporation Vecteurs et genes a expression accrue
CA2331258C (fr) * 1998-06-12 2011-09-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Augmentation de l'activation des cellules b et de la secretion d'immunoglobuline par co-stimulation de recepteurs de l'antigene et d'ebv gp350/220
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
ITMI20031942A1 (it) * 2003-10-09 2005-04-10 Indena Spa Dna codificante p185^neu e suoi usi terapeutici
ITMI20041965A1 (it) * 2004-10-15 2005-01-15 Augusto Amici "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici"
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2010135514A2 (fr) * 2009-05-22 2010-11-25 Intelligent Medical Devices, Inc. Sondes et amorces optimisées et leurs procédés d'utilisation pour la détection, le criblage, la quantification, l'isolement et le séquençage de cytomégalovirus et de virus epstein-barr
US10461635B1 (en) * 2018-05-15 2019-10-29 Analog Devices Global Unlimited Company Low VIN high efficiency chargepump

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069310D1 (en) * 1980-11-03 1984-10-31 Itt Ind Gmbh Deutsche Binary mos ripple carry parallel adder/subtractor and appropriate adding/subtracting stage
US4707358A (en) * 1984-01-30 1987-11-17 The University Of Chicago Vaccine against Epstein-Barr Virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
EP0173254B1 (fr) * 1984-08-23 1991-07-24 Hans Joachim Wolf Séquences d'ADN du génome d'EBV, molécules recombinantes d'ADN, procédés pour la production des antigènes relatifs à EBV, compositions diagnostiques et compositions pharmaceutiques contenant les dits antigènes
EP0312164A1 (fr) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification d'antigènes recombinants du virus epstein-barr à partir de cellules vero, cellules de levure ou cellules L
CA2090295A1 (fr) * 1992-02-03 1993-08-04 Anthony B. Nesburn Procede pour l'expression de la glycoproteine e du virus de l'herpes simplex de type-1 et methodes d'utilisation
WO1993019092A1 (fr) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
WO1994020138A1 (fr) * 1993-03-12 1994-09-15 Theratech, Inc. Proteine du virus epstein-barr obtenue par recombinaison et son utilisation comme vaccin
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220

Also Published As

Publication number Publication date
EP0769056B1 (fr) 2001-12-05
FI964186L (fi) 1996-12-17
SK134396A3 (en) 1997-06-04
FI20075338A7 (fi) 2007-05-10
UA47403C2 (uk) 2002-07-15
EP0769056A4 (fr) 1998-03-04
NO319382B1 (no) 2005-07-25
PL316941A1 (en) 1997-02-17
US6054130A (en) 2000-04-25
CN1152940A (zh) 1997-06-25
CN1495262A (zh) 2004-05-12
JPH10501687A (ja) 1998-02-17
SK283446B6 (sk) 2003-07-01
DE69524415T2 (de) 2002-08-01
US5824508A (en) 1998-10-20
NO964431L (no) 1996-12-11
HUT75831A (en) 1997-05-28
LV11803A (lv) 1997-06-20
KR100380953B1 (ko) 2003-10-10
AU2383895A (en) 1995-11-10
US6458364B1 (en) 2002-10-01
FI118224B (fi) 2007-08-31
JP3447743B2 (ja) 2003-09-16
CZ292283B6 (cs) 2003-08-13
FI20075338L (fi) 2007-05-10
PT769056E (pt) 2002-05-31
JP4317786B2 (ja) 2009-08-19
FI964186A0 (fi) 1996-10-18
CZ305496A3 (en) 1997-10-15
JP2005333990A (ja) 2005-12-08
CN1118573C (zh) 2003-08-20
PL181881B1 (pl) 2001-09-28
NO964431D0 (no) 1996-10-18
HU9602894D0 (en) 1996-12-30
CA2187908A1 (fr) 1995-10-26
JP2004290199A (ja) 2004-10-21
BR9507473A (pt) 1997-09-23
ES2170144T3 (es) 2002-08-01
AU707837B2 (en) 1999-07-22
WO1995028488A1 (fr) 1995-10-26
EP0769056A1 (fr) 1997-04-23
DE69524415D1 (de) 2002-01-17
TW496897B (en) 2002-08-01
RU2178807C2 (ru) 2002-01-27
MY114769A (en) 2003-01-31
HU221647B1 (hu) 2002-12-28
DK0769056T3 (da) 2002-04-02
JP2003230396A (ja) 2003-08-19
CA2187908C (fr) 2002-09-17
ATE210184T1 (de) 2001-12-15
CN100415895C (zh) 2008-09-03

Similar Documents

Publication Publication Date Title
Robbins et al. Pseudorabies virus gene encoding glycoprotein gIII is not essential for growth in tissue culture
IE58030B1 (en) Vaccines based on membrane bound proteins and process for making them
US6207168B1 (en) Vaccine composition for herpes simplex virus and methods of using
JPH03503478A (ja) 組換えｃｍｖ中和タンパク
Bowles et al. The ICP0 protein of equine herpesvirus 1 is an early protein that independently transactivates expression of all classes of viral promoters
AU707837B2 (en) Non-splicing variants of gp350/220
US20130064844A1 (en) Non-splicing variants of gp350/220
US5807557A (en) Soluble herpesvirus glycoprotein complex
US6713296B1 (en) VZV gene, mutant VZV and immunogenic compositions
AU681131B2 (en) Recombinant epstein-barr virus protein and its use in vaccine